Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher & Provide Over...
13 October 2016 - 10:00PM
Business Wire
Webcast to be held October 28, 2016 at 10:00
a.m. EDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapeutics to treat serious and
rare diseases, today announced that it will host an educational
webinar on facioscapulohumeral muscular dystrophy (FSHD) and the
Company’s Phase 2 clinical trial of ACE-083 in FSHD patients. The
webinar will be led by neuromuscular disease expert, Jeffrey
Statland, M.D., M.P.H., and Acceleron management, at 10:00 a.m. EDT
on Friday, October 28, 2016.
Dr. Statland is an assistant professor of neurology at the
University of Kansas Medical Center with both clinical and research
training in neuromuscular diseases. His primary research interest
is in FSHD, one of the most prevalent forms of muscular dystrophy,
characterized by a progressive loss of muscle strength. During the
webinar, Dr. Statland will provide an overview of FSHD, its
clinical manifestations and unmet medical need. Acceleron
management will provide an overview of ACE-083 and the design of
the upcoming Phase 2 clinical trial. At the end of the
presentation, Dr. Statland and Acceleron management will be
available to answer questions from the call participants.
Conference Call and Webcast
Details
Date:
Friday, October 28, 2016 Time: 10:00 a.m. (EDT)
Participants can access the live conference call by dialing
877-312-5848 (domestic) or 253-237-1155 (international) and refer
to the Acceleron FSHD Call.
The live webcast can be accessed on the Investors page of the
Company's website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two
hours after the event on the Acceleron website.
About ACE-083
ACE-083 is a therapeutic candidate that acts as a ligand trap
for members in the transforming growth factor-beta (TGF-β)
superfamily involved in the regulation of muscle mass and strength.
ACE-083 has been designed to increase muscle mass and strength
selectively in the muscles into which the drug is
administered. Acceleron is developing ACE-083 for diseases in
which improved muscle strength in a specific set of muscles may
provide a clinical benefit, such as facioscapulohumeral muscular
dystrophy.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of innovative
therapeutics to treat serious and rare diseases. Its pioneering
research platform leverages the powerful biology behind the body’s
ability to rebuild and repair its own cells and tissues. This
approach to drug discovery has generated four therapeutic
candidates that are currently in clinical trials. The Company’s
lead therapeutic candidate, luspatercept, is being evaluated in
Phase 3 studies for the treatment of the hematologic diseases,
myelodysplastic syndromes (MDS) and beta-thalassemia under a global
partnership with Celgene Corp. Acceleron is also advancing clinical
programs in the fields of oncology and neuromuscular diseases and
has a comprehensive preclinical research effort targeting fibrotic
and other serious diseases.
For more information, please visit www.acceleronpharma.com. Follow Acceleron on
social media: @AcceleronPharma and LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161013005351/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Senior
Director, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Apr 2024 to May 2024
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From May 2023 to May 2024